SHARON, Pa., Nov. 14 /PRNewswire-FirstCall/ -- NanoLogix, Inc. , a nano-biotechnology company engaged in the research, development and commercialization of technologies for alternative sources of fuel, today announced that it has appointed William A. Hartman as Senior Vice President. Previously, Mr. Hartman spent over 16 years in executive management positions at TRW-Chassis Systems, Inc., the multi-billion dollar operating unit of TRW, Inc., now known as TRW Automotive, a leading global supplier to the automotive industry. Prior to TRW-Chassis, Mr. Hartman spent 20 years with Ford Motor Company in various planning, engineering, manufacturing, and quality control management positions.
Mr. Hartman commented, “The automotive industry, under constant pressure to create zero-emission vehicles, is increasingly turning to hydrogen fuel for its eco-friendly, clean-burning attributes. Major auto manufacturers are beginning to produce fleets of hydrogen-powered test vehicles, and indicate a total conversion to hydrogen fuel is possible. NanoLogix has succeeded in increasing hydrogen output by using its bioreactor technologies and readily available organic material. I am excited to help bring NanoLogix’ technologies to commercial markets worldwide.”
Mitchell Felder, M.D., NanoLogix Chairman of the Board and Chief Executive Officer, stated, “Bill’s diversified management experience and strong track record of performance further enriches our management team. We are confident that Bill will play a key role in maximizing our operational and cost efficiencies and helping us to build new, global partnerships.”
Most recently, Mr. Hartman was Director of Chassis Purchasing, where he was responsible for $1 billion in direct materials. During his tenure, his accomplishments included creating a centralized organization that improved efficiency by 30% and reduced direct materials by 41%. In his role as Director of Modular Chassis Systems Strategic Business Unit, Mr. Hartman personally sold programs resulting in $1.5 billion in annual business. With fiscal responsibility for all modular chassis systems worldwide, his development of best practices resulted in a 50% reduction in labor costs, a decrease in space density by 60%, a 90% decrease in inventory, and 98% quality improvement compared to original equipment built in-house modules.
Mr. Hartman’s previous positions included TRW-Chassis Systems included Director of Marketing and Planning and Chief Engineer of Advanced Product/Process Development. Since 2000, Mr. Hartman has provided technical consulting in the areas of engineering, manufacturing, quality and purchasing as President of The Hartman Group. Mr. Hartman holds an M.S. in Industrial Administration from the University of Michigan and a B.S. in Mechanical Engineering from Youngstown State University.
About NanoLogix, Inc.
NanoLogix is an industry innovator in the research, development and commercialization of nano-biotechnologies, applications and processes. The Company owns or has the rights to 32 patented technologies and also has 22 pending patent applications. The Company is currently focused on the production of hydrogen from agricultural feedstock, industrial wastewater and municipal waste streams to create new sources of energy. NanoLogix is presently operating a hydrogen bioreactor at Welch’s Food and has recently signed an agreement with the City of Erie Wastewater Treatment Plant for a prototype bioreactor installation. Additionally, NanoLogix develops and markets diagnostic test kits for use in early detection of infectious human diseases, and owns a patent for the non-toxic induction of apoptosis (‘cell suicide’) for the treatment of cancer. For more information on the Company, visit http://www.nanologix.net.
This press release contains statements, which may constitute “forward- looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Contacts: NanoLogix, Inc. Investor Relations 724-346-1302 Andrew Barwicki 516-662-9461 andrew@barwicki.com or Peter Clark OTC Financial Network 781-444-6100x629 peter@otcfn.comwww.otcfn.com/nnlx
NanoLogix, Inc.
CONTACT: NanoLogix, Inc., +1-724-346-1302, or investors, Andrew Barwicki,+1-516-662-9461, or andrew@barwicki.com, or Peter Clark of OTC FinancialNetwork, +1-781-444-6100 x 629, or peter@otcfn.com, for NanoLogix, Inc.
